NEOPLASIA

Scope & Guideline

Connecting minds for a future free of cancer.

Introduction

Welcome to your portal for understanding NEOPLASIA, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1476-5586
PublisherELSEVIER SCIENCE INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 1999 to 2024
AbbreviationNEOPLASIA / Neoplasia
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

The journal "NEOPLASIA" is dedicated to advancing the understanding of cancer biology, treatment modalities, and therapeutic innovations. It emphasizes the integration of molecular biology, genetics, and clinical research to enhance cancer management and patient outcomes.
  1. Cancer Biology and Mechanisms:
    Research focused on understanding the underlying biological mechanisms of cancer, including genetic mutations, signaling pathways, and cellular processes that contribute to tumorigenesis.
  2. Therapeutic Targets and Drug Development:
    Exploration of new therapeutic targets and the development of innovative drugs, including small molecules, monoclonal antibodies, and immunotherapeutic agents.
  3. Tumor Microenvironment and Immune Interactions:
    Investigation of the tumor microenvironment's role in cancer progression, immune evasion, and response to therapy, including studies on tumor-infiltrating lymphocytes and immune checkpoint inhibitors.
  4. Clinical Applications and Patient Outcomes:
    Studies that bridge laboratory research with clinical applications, focusing on treatment efficacy, patient stratification, and real-world evidence to improve cancer care.
  5. Genomic and Epigenomic Profiling:
    Research utilizing genomic and epigenomic technologies to identify biomarkers for early detection, prognosis, and personalized treatment strategies.
The journal "NEOPLASIA" has embraced several trending and emerging themes that reflect the forefront of cancer research and therapeutic innovation. These themes indicate a shift towards more personalized and mechanistic approaches in oncology.
  1. Immunotherapy and Immune Modulation:
    There is a significant increase in studies exploring immunotherapy, including checkpoint inhibitors, CAR T-cell therapy, and combination strategies that enhance anti-tumor immune responses.
  2. Targeting the Tumor Microenvironment:
    Emerging research focuses on the tumor microenvironment, including the roles of stromal cells, extracellular matrix components, and immune cell interactions in cancer progression and therapy resistance.
  3. Precision Medicine and Genomic Profiling:
    A trend towards personalized medicine is evident, with increasing studies on genomic profiling, biomarker discovery, and targeted therapies tailored to individual patient profiles.
  4. Metabolic Reprogramming in Cancer:
    Research investigating how cancer cells alter their metabolism to support growth and survival is gaining traction, particularly in understanding drug resistance and therapeutic vulnerabilities.
  5. Artificial Intelligence and Machine Learning in Oncology:
    The integration of AI and machine learning technologies in cancer research and diagnostics is rapidly emerging, with studies focusing on predictive modeling, imaging analysis, and treatment optimization.

Declining or Waning

As the field of oncology evolves, certain research areas within "NEOPLASIA" have shown a decline in focus, potentially reflecting shifts in scientific interest or advancements in cancer treatment strategies.
  1. Traditional Chemotherapy Studies:
    Research centered on conventional chemotherapy regimens appears to be waning as newer targeted therapies and immunotherapies gain prominence in clinical practice.
  2. Single-Agent Drug Studies:
    There is a noticeable decrease in studies focusing solely on single-agent drug efficacy, with a growing trend towards combination therapies that target multiple pathways.
  3. Basic Histopathology:
    While foundational histopathological studies remain important, there is a shift towards advanced molecular and genomic approaches that provide deeper insights into cancer biology.
  4. Non-Molecular Biomarkers:
    Research on traditional non-molecular biomarkers is less prevalent as the field moves towards integrating molecular and genetic markers for better prognostic accuracy.

Similar Journals

NEOPLASMA

Advancing the Frontiers of Cancer Research
Publisher: AEPRESS SROISSN: 0028-2685Frequency: 6 issues/year

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

Cancer Research Communications

Bridging gaps in cancer knowledge and practice.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

ONCOLOGY RESEARCH

Pioneering Insights in Oncology and Medicine
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Molecular and Clinical Oncology

Innovating cancer care through rigorous research.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Unraveling the Complexities of Cancer Biology
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

CANCER CELL

Unraveling the Mysteries of Tumor Biology
Publisher: CELL PRESSISSN: 1535-6108Frequency: 12 issues/year

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

INTERNATIONAL JOURNAL OF ONCOLOGY

Empowering breakthroughs in oncology and patient care.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

CANCER RESEARCH

Shaping the future of cancer research with excellence.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

MOLECULAR CANCER THERAPEUTICS

Innovating the future of oncology, one study at a time.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Annual Review of Cancer Biology

Charting New Directions in Cancer Studies
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.